Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioCryst Pharmaceuticals (BCRX)
:BCRX
Holding BCRX?
Track your performance easily
BCRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.03 - $8.88
Previous CloseN/A
Volume537.69K
Average Volume (3M)1.85M
Market Cap
$1.67B
Enterprise Value$2.08B
Total Cash (Recent Filing)$54.65M
Total Debt (Recent Filing)$25.48M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Feb 19, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding207,132,570
10 Day Avg. Volume1,585,119
30 Day Avg. Volume1,846,261
Standard Deviation0.21
R-Squared0.19
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.09
Price to Cash Flow (P/CF)51.10
P/FCF Ratio51.00
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue5.05
Enterprise Value/Gross Profit6.38
Enterprise Value/Ebitda-86.41
Forecast
1Y Price Target
$16.00Price Target Upside98.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
BioCryst News
PremiumCompany Announcements
BioCryst Pharmaceuticals Reports Strong Q3 2024 Results
Ownership Overview
6.71% Insiders
17.77% Mutual Funds
0.08% Other Institutional Investors
59.26% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BCRX FAQ
What was BioCryst Pharmaceuticals’s price range in the past 12 months?
BioCryst Pharmaceuticals lowest stock price was $4.03 and its highest was $8.88 in the past 12 months.
What is BioCryst Pharmaceuticals’s market cap?
BioCryst Pharmaceuticals’s market cap is $1.67B.
When is BioCryst Pharmaceuticals’s upcoming earnings report date?
BioCryst Pharmaceuticals’s upcoming earnings report date is Feb 19, 2025 which is in 41 days.
How were BioCryst Pharmaceuticals’s earnings last quarter?
BioCryst Pharmaceuticals released its earnings results on Nov 04, 2024. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.069 by -$0.001.
Is BioCryst Pharmaceuticals overvalued?
According to Wall Street analysts BioCryst Pharmaceuticals’s price is currently Undervalued.
Does BioCryst Pharmaceuticals pay dividends?
BioCryst Pharmaceuticals does not currently pay dividends.
What is BioCryst Pharmaceuticals’s EPS estimate?
BioCryst Pharmaceuticals’s EPS estimate is -0.08.
How many shares outstanding does BioCryst Pharmaceuticals have?
BioCryst Pharmaceuticals has 207,132,570 shares outstanding.
What happened to BioCryst Pharmaceuticals’s price movement after its last earnings report?
BioCryst Pharmaceuticals reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.069. Following the earnings report the stock price went down -12.811%.
Which hedge fund is a major shareholder of BioCryst Pharmaceuticals?
Among the largest hedge funds holding BioCryst Pharmaceuticals’s share is Deerfield Management Company, LP. It holds BioCryst Pharmaceuticals’s shares valued at 62M.
---
BioCryst Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (98.76% Upside)
$16.00 (98.76% Upside)
Blogger Sentiment
Bullish
BCRX Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 574.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.22%
12-Months-Change
Fundamentals
Return on Equity
26.42%
Trailing 12-Months
Asset Growth
-6.06%
Trailing 12-Months
Company Description
BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of novel oral and small-molecule therapeutics. The company operates in the pharmaceutical sector and is committed to addressing the unmet medical needs of patients with rare diseases. BioCryst's core products include treatments for hereditary angioedema (HAE) and other rare diseases, with Orladeyo (berotralstat) being one of its flagship drugs.
---
BCRX Company Deck
---
BCRX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth for Orladeyo, successful addition of new prescribers, and significant progress in clinical trials and financial performance, indicating positive momentum. However, challenges remain with the Medicare paid rate and potential royalty impacts. Overall, the positive developments significantly outweigh the challenges.Read More>---
BCRX Stock 12 Month Forecast
Average Price Target
$16.00
▲(98.76% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
Bluebird Bio
―
Best Analysts Covering BCRX
1 Year
1 Year Success Rate
10/20 ratings generated profit
1 Year Average Return
+5.54%
assigned a buy rating 2 months ago
Copying Liisa Bayko's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +5.54% per trade.
---